Physician profile
Melissa Klein
NPI 1821093675
$6,949.99
in general payments reported to CMS, 2019-2025
47 companies · $74.37 in 2025
The $74.37 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,137 · 2020: $653 · 2021: $1,008 · 2022: $1,602 · 2023: $1,423 · 2024: $1,051 · 2025: $74.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531 · Education: $17.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.75 |
| Education | $17.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $927.45 | 2021-2024 | Botox, Ubrelvy, Qulipta |
| Ucb, INC. | $565.99 | 2019-2024 | Briviact |
| Amgen INC. | $525.62 | 2019-2023 | Aimovig |
| Allergan, INC. | $481.17 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $442.51 | 2019-2025 | |
| Lilly USA, LLC | $426.39 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Teva Pharmaceuticals USA, INC. | $425.28 | 2019-2024 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $405.31 | 2019-2022 | |
| Argenx US, INC. | $375.48 | 2022-2024 | Vyvgart |
| Biogen, INC. | $288.44 | 2019-2024 | Vumerity, Tysabri |
| Csl Behring | $199.08 | 2019-2024 | Hizentra |
| Avanir Pharmaceuticals, INC. | $175.47 | 2019-2022 | |
| Acorda Therapeutics, INC | $161.54 | 2019-2022 | |
| Sk Life Science, INC. | $124.88 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $121.22 | 2020-2024 | Ingrezza, Ongentys |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.